MDGL
Price
$221.98
Change
+$8.86 (+4.16%)
Updated
Dec 4, 6:59 PM EST
80 days until earnings call
PDSB
Price
$5.28
Change
+$0.03 (+0.57%)
Updated
Dec 4, 6:59 PM EST
115 days until earnings call
Ad is loading...

Analysis and predictions MDGL vs PDSB

Header iconMDGL vs PDSB Comparison
Open Charts MDGL vs PDSBBanner chart's image
Madrigal Pharmaceuticals
Price$221.98
Change+$8.86 (+4.16%)
Volume$136.86K
CapitalizationN/A
PDS Biotechnology
Price$5.28
Change+$0.03 (+0.57%)
Volume$290.79K
CapitalizationN/A
View a ticker or compare two or three
MDGL vs PDSB Comparison Chart

Loading...

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
VS
MDGL vs. PDSB commentary
Dec 05, 2023

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDGL is a Buy and PDSB is a Hold.

COMPARISON
Comparison
Dec 05, 2023
Stock price -- (MDGL: $221.98 vs. PDSB: $5.28)
Brand notoriety: MDGL and PDSB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MDGL: 33% vs. PDSB: 54%
Market capitalization -- MDGL: $3.9B vs. PDSB: $183.54M
MDGL [@Biotechnology] is valued at $3.9B. PDSB’s [@Biotechnology] market capitalization is $183.54M. The market cap for tickers in the [@Biotechnology] industry ranges from $464.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.29B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MDGL’s FA Score shows that 0 FA rating(s) are green whilePDSB’s FA Score has 0 green FA rating(s).

  • MDGL’s FA Score: 0 green, 5 red.
  • PDSB’s FA Score: 0 green, 5 red.
According to our system of comparison, MDGL is a better buy in the long-term than PDSB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MDGL’s TA Score shows that 6 TA indicator(s) are bullish while PDSB’s TA Score has 5 bullish TA indicator(s).

  • MDGL’s TA Score: 6 bullish, 4 bearish.
  • PDSB’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, MDGL is a better buy in the short-term than PDSB.

Price Growth

MDGL (@Biotechnology) experienced а +12.51% price change this week, while PDSB (@Biotechnology) price change was -10.51% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.58%. For the same industry, the average monthly price growth was +26.31%, and the average quarterly price growth was +25.79%.

Reported Earning Dates

MDGL is expected to report earnings on Feb 22, 2024.

PDSB is expected to report earnings on Mar 28, 2024.

Industries' Descriptions

@Biotechnology (+5.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for MDGL with price predictions.
OPEN
A.I.dvisor published
a Summary for PDSB with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
MDGL($3.9B) has a higher market cap than PDSB($184M). MDGL YTD gains are higher at: -23.521 vs. PDSB (-60.000). PDSB has higher annual earnings (EBITDA): -48.62M vs. MDGL (-336.4M). MDGL has more cash in the bank: 232M vs. PDSB (54.3M). PDSB has less debt than MDGL: PDSB (23.6M) vs MDGL (117M). MDGL (0) and PDSB (0) have equivalent revenues.
MDGLPDSBMDGL / PDSB
Capitalization3.9B184M2,117%
EBITDA-336.4M-48.62M692%
Gain YTD-23.521-60.00039%
P/E RatioN/AN/A-
Revenue00-
Total Cash232M54.3M427%
Total Debt117M23.6M496%
FUNDAMENTALS RATINGS
MDGL vs PDSB: Fundamental Ratings
MDGL
PDSB
OUTLOOK RATING
1..100
4884
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
62
Fair valued
PROFIT vs RISK RATING
1..100
77100
SMR RATING
1..100
10099
PRICE GROWTH RATING
1..100
3561
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
75n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PDSB's Valuation (62) in the Pharmaceuticals Major industry is somewhat better than the same rating for MDGL (96) in the Pharmaceuticals Other industry. This means that PDSB’s stock grew somewhat faster than MDGL’s over the last 12 months.

MDGL's Profit vs Risk Rating (77) in the Pharmaceuticals Other industry is in the same range as PDSB (100) in the Pharmaceuticals Major industry. This means that MDGL’s stock grew similarly to PDSB’s over the last 12 months.

PDSB's SMR Rating (99) in the Pharmaceuticals Major industry is in the same range as MDGL (100) in the Pharmaceuticals Other industry. This means that PDSB’s stock grew similarly to MDGL’s over the last 12 months.

MDGL's Price Growth Rating (35) in the Pharmaceuticals Other industry is in the same range as PDSB (61) in the Pharmaceuticals Major industry. This means that MDGL’s stock grew similarly to PDSB’s over the last 12 months.

MDGL's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as PDSB (100) in the Pharmaceuticals Major industry. This means that MDGL’s stock grew similarly to PDSB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MDGLPDSB
RSI
ODDS (%)
Bearish Trend 1 day ago
77%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
85%
Momentum
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
89%
MACD
ODDS (%)
Bullish Trend 5 days ago
78%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
86%
Advances
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 19 days ago
85%
Declines
ODDS (%)
Bearish Trend 26 days ago
81%
Bearish Trend 6 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
81%
Aroon
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
84%
View a ticker or compare two or three
Ad is loading...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
BOAT28.930.10
+0.35%
SonicShares™ Global Shipping ETF
DCF7.970.01
+0.13%
BNY Mellon Alcentra Global Credit Income 2024 Target Term Fund
PHO57.430.03
+0.05%
Invesco Water Resources ETF
AGIH24.18N/A
N/A
iShares Inflation Hdg U.S. Aggt Bd ETF
IBDX24.34-0.11
-0.45%
iShares iBonds Dec 2032 Term Corp ETF

PDSB and

Correlation & Price change

A.I.dvisor indicates that over the last year, PDSB has been loosely correlated with AXON. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if PDSB jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PDSB
1D Price
Change %
PDSB100%
+0.57%
AXON - PDSB
43%
Loosely correlated
+2.06%
MDGL - PDSB
38%
Loosely correlated
+4.16%
VCYT - PDSB
37%
Loosely correlated
-1.77%
VERA - PDSB
35%
Loosely correlated
+0.22%
ARRY - PDSB
35%
Loosely correlated
-1.72%
More